BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
61.37
+2.51 (4.26%)
At close: May 12, 2025, 4:00 PM
62.00
+0.63 (1.03%)
After-hours: May 12, 2025, 7:59 PM EDT
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $745.15M in the quarter ending March 31, 2025, with 14.84% growth. This brings the company's revenue in the last twelve months to $2.95B, up 19.36% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm)
$2.95B
Revenue Growth
+19.36%
P/S Ratio
3.96
Revenue / Employee
$970,469
Employees
3,040
Market Cap
11.77B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BMRN News
- 15 hours ago - BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings - PRNewsWire
- 11 days ago - BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance - PRNewsWire
- 25 days ago - BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET - PRNewsWire
- 5 weeks ago - BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion - Seeking Alpha
- 5 weeks ago - BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria - PRNewsWire
- 7 weeks ago - BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting - PRNewsWire
- 2 months ago - BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA - PRNewsWire